Oruka Therapeutics (ORKA) Long-Term Investments (2016 - 2026)
Oruka Therapeutics (ORKA) posted quarterly Long-Term Investments of $107.1 million for Q1 2026, up 347.22% year-over-year from $24.0 million in Q1 2025, and down 24.85% quarter-over-quarter from $142.5 million in Q4 2025.
Oruka Therapeutics (ORKA) Long-Term Investments (2016 - 2026) Analysis & Trends
Oruka Therapeutics' Long-Term Investments history runs 4 years deep, the most recent figure standing at $107.1 million for Q1 2026.
- In Q1 2026, Long-Term Investments rose 347.22% year-over-year to $107.1 million; the TTM figure through Mar 2026 stood at $107.1 million (up 347.22% YoY), while the FY2025 annual figure was $142.5 million, up 688.86% from the prior year.
- Long-Term Investments for Q1 2026 stood at $107.1 million, down from $142.5 million in the prior quarter.
- The five-year high for Long-Term Investments was $151.8 million in Q3 2025, with the low at $18.1 million in Q4 2024.
- The 3-year median for Long-Term Investments is $65.5 million (2025), against an average of $77.8 million.
- The sharpest annual moves came in 2025 and 2026: Long-Term Investments jumped 688.86% in 2025, then surged 347.22% in 2026.
- Oruka Therapeutics' Long-Term Investments stood at $18.1 million in 2024, then surged by 688.86% to $142.5 million in 2025, then declined by 24.85% to $107.1 million in 2026.
- Business Quant data shows ORKA's Long-Term Investments at $107.1 million in Q1 2026, $142.5 million in Q4 2025, and $151.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Oruka Therapeutics | 6.98 Bn | 5.25 Bn | - | 252.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 252.02 Mn |
| Mar 31, 2026 | 107.12 Mn |
| Dec 31, 2025 | 142.54 Mn |
| Sep 30, 2025 | 151.76 Mn |
| Jun 30, 2025 | 23.05 Mn |
| Mar 31, 2025 | 23.95 Mn |
| Dec 31, 2024 | 18.07 Mn |
| Dec 31, 2016 | 2.35 Mn |
| Sep 30, 2016 | 3.97 Mn |
| Jun 30, 2016 | 5.01 Mn |
| Mar 31, 2016 | 5.31 Mn |